• News
  • Top stocks to buy: Stock recommendations for the week starting July 14, 2025 - check list

Top stocks to buy: Stock recommendations for the week starting July 14, 2025 - check list

Stock market recommendations: Motilal Oswal Financial Services recommends Suzlon and Glenmark Pharma as top stock picks for the week starting July 14, 2025. Suzlon anticipates healthy order inflows, potentially reaching 6.5GW by FY26, benefiting from favorable policy changes and strategic initiatives.
Top stocks to buy: Stock recommendations for the week starting July 14, 2025 - check list
Top stocks to buy (AI image)
Stock market recommendations: According to Motilal Oswal Financial Services Ltd, the top stock picks for the week (starting July 14, 2025) are Suzlon, and Glenmark Pharma. Let’s take a look:
Stock Name

CMP (Rs)

Target (Rs)

Upside (%)

Suzlon

66

82

24%

Glenmark

2175

2430

12%

SuzlonSuzlon new order outlook remains healthy with expected order inflow of ~4GW in FY26, including potential ~1.5GW NTPC orders, which implies total potential OB of ~6.5GW by FY26 end. EPC share is likely to rise from 20% now to ~50% in the medium term, improving execution visibility. Revised list of Models & Manufacturers (RLMM) mandating local content for key components in wind turbines is likely to be formally adopted in 2QFY26. Gradual Inter-state transmission system (ISTS) waiver phase-out will support smoother project execution. Suzlon stands to benefit from proactive land acquisition and EPC expansion initiatives. Cash conversion cycle is expected to improve by 30-35 days which will enhance balance sheet strength & generate higher free cash flow, supporting sustainable RoEs.Glenmark PharmaGlenmark’s subsidiary Ichnos Glenmark Innovation (IGI) has signed an exclusive licensing agreement with AbbVie, a diversified biopharma leader, for its oncology product ISB-2001, validating clinical & commercial potential of IGI’s BEAT® protein platform.
The $700m upfront—world’s 4th largest payment—along with $1.2b in milestones, boosts R&D monetization. Tiered double-digit royalties offer annuity income, while ANDA pipeline expansion & domestic reset further support growth. AbbVie will commercialize ISB-2001 in developed markets, while Glenmark retains rights in emerging markets. Improved leverage and a domestic reset underpin 11%/17%/20% sales/EBITDA/PAT CAGR over FY25-27. We add INR470/share NPV to arrive at a TP of INR2,430, supported by its pivot toward innovation-led growth.Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India. Always consult with a qualified investment advisor or financial planner before making any investment decisions.
author
About the Author
TOI Business Desk

The TOI Business Desk is a vigilant and dedicated team of journalists committed to delivering the latest and most relevant business news from around the world to readers of The Times of India. The primary focus of the TOI Business Desk is to keep a watchful eye on the global business landscape, covering a wide spectrum of industries, markets, economic trends, in-depth analysis, exclusive reports and breaking stories that impact businesses and economies. With a mission to provide valuable insights and updates, the desk ensures that TOI readers are well-informed about the ever-changing and dynamic world of commerce and can navigate the complexities of the business world.

End of Article
Follow Us On Social Media